Full Press Release Details
Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U S Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities.
RYTM
Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U S Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities
Key Takeaway: Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U S Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities